Bidding for Onyx Pharma (ONXX) Done? Not Likely...
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Novartis (NVS), Pfizer (PFE) Out on Onyx (ONXX); Is Amgen (AMGN) the Sole Runner?
August 13, 2013 3:23 PM EDTOnyx Pharma (Nasdaq: ONXX) shares dropped down for a second time today on this roller coaster Tuesday.
First, the stock got a boost following comments from Novartis (NYSE: NVS) chairman Joerg Reinhardt, who... More
Brean Capital Boosts Onyx Pharma (ONXX) Price Target to $160
July 1, 2013 2:41 PM EDTBrean Capital today maintained a Buy rating on Onyx Pharmaceuticals (NASDAQ: ONXX) and raised its price target to $160.00 (from $115.00). The change follows news Onyx Pharmaceuticals received an unsolicited bid from Amgen Inc. (Nasdaq: AMGN).
"Our $115... More
Maxim Group Downgrades Onyx Pharmaceuticals (ONXX) to Hold
July 1, 2013 11:18 AM EDTMaxim Group downgraded Onyx Pharmaceuticals (NASDAQ: ONXX) from Buy to Hold.
For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $86.82 yesterday, with a 52 week range of $63.00-$101.57.... More
Onyx Pharma (ONXX) Reports $120/Share Bid from Amgen (AMGN); Hires Advisor
July 1, 2013 6:24 AM EDTOnyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today confirmed that it has received and rejected an unsolicited proposal from Amgen Inc. (Nasdaq: AMGN) to acquire all of Onyx's outstanding shares and share equivalents for $120 per share in cash, subject to due diligence and other conditions. The Board of Directors of Onyx had evaluated the proposal made by Amgen with the assistance of its financial and legal advisors and concluded that... More
